Evaluating the effect of metabolic traits on oral and oropharyngeal cancer risk using Mendelian randomization

Mark Gormley, BDS* [1,2], Tom Dudding, PhD[2], Steven J Thomas, PhD[2], Jessica Tyrrell, PhD[3], Andrew R Ness, PhD[4], Miranda Pring, PhD[2], Danny Legge, PhD[5], George Davey Smith, FRS[1], Rebecca C Richmond, PhD[1], Emma E Vincent, PhD[1,5§], Caroline Bull, PhD[1,5§]

[1] MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

[2] Bristol Dental Hospital and School, University of Bristol, Bristol, UK.

[3] University of Exeter Medical School, RILD Building, RD&E Hospital, Exeter, UK.

[4] University Hospitals Bristol and Weston NHS Foundation Trust National Institute for Health Research Bristol Biomedical Research Centre, University of Bristol, Bristol, UK

[5] Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

§ Joint senior authors

* Corresponding author: mark.gormley@bristol.ac.uk

Abstract

A recent World Health Organization report states that at least 40% of all cancer cases may be preventable, with smoking, alcohol consumption and obesity identified as three of the most important modifiable lifestyle factors. Given the significant decline in smoking rates, particularly within developing countries, other potentially modifiable risk factors for head and neck cancer warrant investigation. Obesity and related metabolic disorders such as type 2 diabetes and hypertension have been associated with head and neck cancer risk in multiple observational studies. However, obesity has also been correlated with smoking, with bias, confounding or reverse causality possibly explaining these findings. To overcome the challenges of observational studies, we conducted two-sample Mendelian randomization (inverse variance weighted (IVW) method) using genetic variants which were robustly associated with obesity, T2D and hypertension in genome-wide association studies (GWAS). Outcome data was taken from the largest available GWAS of 6,034 oral and oropharyngeal cases, with 6,585 controls. We found limited evidence of a causal effect of genetically proxied body mass index (OR IVW 0.89, 95%CI 0.72–1.09, p = 0.26 per 1 SD in BMI (4.81 kg/m2)) on oral and oropharyngeal cancer risk. Similarly, there was limited evidence for related traits including type 2 diabetes and hypertension. Smoking appears to act as a mediator in the relationship between obesity and head and neck cancer.

Introduction

Head and neck squamous cell carcinoma (HNC), which includes cancers of the oral cavity and oropharynx is the 7th most common cancer, accounting for more than 660,000 new cases and 325,000 deaths annually worldwide (Johnson et al., 2020; Sung et al., 2021). Established risks include tobacco use, alcohol consumption (Hashibe et al., 2009) and human papillomavirus (HPV) infection, mainly associated with oropharyngeal cancer and thought to be sexually transmitted (Gillison, Chaturvedi, Anderson, & Fakhry, 2015). A recent World Health Organization (WHO) report states that at least 40% of all cancer cases may be preventable, with smoking, alcohol consumption and obesity identified as three of the most important modifiable lifestyle factors (World Health Organization (WHO), 2022). Smoking behaviour is declining, particularly in developing countries and it has been projected that obesity could even supersede smoking as the primary driver of cancer in the coming decades (World Health Organization (WHO), 2022). Despite changes in smoking rates, the incidence of HNC continues to rise and a changing aetiology has been proposed (Conway, 2018; Thomas, Penfold, Waylen, & Ness, 2018). Therefore, less established risks such as obesity and its related metabolic traits warrant investigation in HNC. However, obesity has been correlated with other HNC risk factors such as smoking (Carreras-Torres et al., 2018), alcohol (Alice R. Carter et al., 2019) and educational attainment (A. R. Carter et al., 2019), meaning independent effects are difficult to establish.

Obesity is now considered to increase the risk of at least 13 different types of cancer including breast, colorectal, gastric and oesophageal (Centers for Disease Control and Prevention, 2021), but the effect on HNC risk remains unclear (World Health Organization

(WHO), 2022). Public health strategies have been unsuccessful in addressing the current obesity epidemic at the population level, which could result in more cancer cases in the years to come (Davey, 2004). Obesity and related metabolic traits such as type 2 diabetes (T2D), hypertension and dyslipidaemia have all been associated with head and neck cancer in multiple observational studies. In the largest pooled analysis, obesity defined by higher body mass index (BMI) was associated with a protective effect for HNC in current smokers (hazard ratio (HR)=0.76, 95% confidence intervals (95%CI) 0.71–0.82, p<0.0001, per 5 kg/m^2) and conversely, a higher risk in never smokers (HR 1.15, 95%CI 1.06–1.24 per 5 kg/m^2, $p < 0.001$) (Gaudet et al., 2015). In the same study, a greater waist circumference (WC) (HR=1.04, 95%CI 1.03–1.05 per 5 cm, p < 0.001) and waist-to-hip ratio (WHR) (HR=1.07, 95%CI 1.05–1.09 per 0.1 unit, $p < 0.001$) were associated with increased HNC risk, which did not vary by smoking status (Gaudet et al., 2015). However, more recent cohort studies have failed to show a clear association between BMI and HNC (Cao et al., 2020; Diaz et al., 2021; Gribsholt et al., 2020; Jiang et al., 2021; Ward et al., 2017). A meta-analysis of observational studies investigating T2D with oral and oropharyngeal subsites, showed an increased risk ratio (RR) of 1.15, 95%CI 1.02–1.29, *P heterogeneity* = 0.277 (Gong, Wei, Yu, & Pan, 2015), a result which is consistent with more recent independent cohorts (Jiang et al., 2021; H.-B. Kim, Kim, Han, & Joo, 2021; S.-Y. Kim, Han, & Joo, 2019; Saarela et al., 2019). Hypertension (defined as a systolic blood pressure (SBP) > 130 mmHg or diastolic blood pressure (DBP) > 85 mmHg), has been correlated with head and neck cancer risk across multiple studies (Christakoudi et al., 2020; H.-B. Kim et al., 2021; S.-Y. Kim et al., 2019; Seo, Kim, Park, Han, & Joo, 2020; Stocks et al., 2012). Nonetheless, selection bias, confounding, or reverse causation may explain the findings from these studies.

91 Mendelian randomization (MR) is an analytical approach which attempts to overcome the
92 challenges of conventional epidemiological studies. The method uses germline genetic
93 single nucleotide polymorphisms (SNPs), which are randomly assorted during meiosis (and
94 fixed at conception), to estimate the causal effects of exposures on disease outcomes
95 (Davey Smith & Hemani, 2014; Sanderson et al., 2022; Smith & Ebrahim, 2003). Using MR,
96 we recently found limited evidence for a role of circulating lipid traits in oral and
97 oropharyngeal cancer risk (Gormley et al., 2021), however other metabolic traits remain
98 untested in an MR framework. Here, we employ a two-sample MR approach, integrating
99 summary-level genetic data from the largest available GWAS for metabolic traits, including
100 obesity measures (BMI, WC, WHR), glycaemic traits (T2D, glycated haemoglobin (HbA_{1c}),
101 fasting glucose (FG), fasting insulin (FI)), and blood pressure (SBP, DBP) to evaluate their
102 causal effect on oral and oropharyngeal cancer risk. Given the potential correlation of
103 metabolic traits and established HNC risk factors, further evaluation of instrument-risk
104 factor effects including smoking, alcohol, risk tolerance (as a proxy for sexual behaviour),
105 and educational attainment was carried out using MR.
106

107 ## Methods

108

109 Two-sample MR was performed using published summary-level data from the largest
110 available GWAS for each metabolic trait. MR makes three key assumptions, as described in
111 **Fig. 1** (Davey Smith & Hemani, 2014; Smith & Ebrahim, 2003).
112



Figure 1. Directed acyclic graph (DAG) depicting Mendelian randomization applied to this study

Genetic variants (G) act as proxies or instruments to investigate if an exposure (X), is associated with a trait e.g., body mass index or disease outcome (Y) e.g., oral/oropharyngeal cancer. Causal inference can be made between X and Y if the following conditions are upheld:

(1) G is a valid instrument, reliably associated with X ('relevance');

(2) no measured (C) or unmeasured (U) confounding of the association between G and the Y ('exchangeability');

(3) there is no independent association of G with Y, except through X ('exclusion restriction principle').

Exposure summary statistics for metabolic traits

To instrument metabolic traits, we selected genetic variants associated ($p < 5 \times 10^{-8}$) with traits of interest identified by previously conducted GWAS (**Supplementary Data 1**). Clumping was performed to ensure single nucleotide polymorphisms (SNPs) in each instrument were independent (linkage disequilibrium $R^2 < 0.001$). Following clumping,

131 genetic instruments were comprised of: 312 SNPs for BMI, from a GWAS meta-analysis of
132 806,834 individuals of European ancestry, including the Genetic Investigation
133 of ANthropometric Traits (GIANT) consortium and UK Biobank (Pulit et al., 2019); 45 SNPs
134 for WC, extracted from the same GWAS (Pulit et al., 2019); 209 SNPs for WHR extracted
135 from a GWAS meta-analysis describing 224,459 individuals of mainly European ancestry
136 (Shungin et al., 2015); 275 SNPs for T2D from the DIAMANTE (DIAbetes Meta-ANalysis of
137 Trans-Ethnic association studies) consortium of 228,499 cases and 1,178,783 controls
138 (Vujkovic et al., 2020); 33 SNPs for FG and 18 SNPs for FI, obtained from a GWAS published
139 by the MAGIC (Meta-Analyses of Glucose and Insulin-Related Traits) Consortium (N =
140 151,188 and 105,056 individuals, respectively) (Lagou et al., 2021); 58 SNPs for HbA_{1c}, taken
141 from a meta-analyses of 159,940 individuals from 82 cohorts of European, African, East
142 Asian, and South Asian ancestry (Wheeler et al., 2017); Finally, 105 and 78 SNPs for SBP and DBP,
143 respectively, were extracted from a GWAS meta-analysis of over 1 million participants in UK
144 Biobank and the International Consortium of Blood Pressure Genome Wide Association
145 Studies (ICBP) (Evangelou et al., 2018) (**Supplementary Data 1**).
146
147 **Outcome summary statistics for oral and oropharyngeal cancer**
148
149 We estimated the effects of metabolic traits on risk of oral and oropharyngeal cancer by
150 extracting exposure SNPs (**Supplementary Data 1**) from the largest available GWAS
151 performed on 6,034 cases and 6,585 controls from 12 studies which were part of the
152 Genetic Associations and Mechanisms in Oncology (GAME-ON) Network (Lesseur et al.,
153 2016). Full details of the included studies, as well as the genotyping and imputation
154 performed, have been described previously (Dudding et al., 2018; Lesseur et al., 2016). In

155 brief, the study population included participants from Europe (45.3%), North America
156 (43.9%) and South America (10.8%). Cancer cases comprised the following the International
157 Classification of Diseases (ICD) codes: oral cavity (C02.0-C02.9, C03.0-C03.9, C04.0-C04.9,
158 C05.0-C06.9) oropharynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9),
159 overlapping (C14 and combination of other sites) and 25 cases with unknown ICD code
160 (other). A total of 954 individuals with cancers of hypopharynx, unknown code or
161 overlapping cancers were excluded. Genomic DNA isolated from blood or buccal cells was
162 genotyped at the Center for Inherited Disease Research (CIDR) using an Illumina OncoArray,
163 custom designed for cancer studies by the OncoArray Consortium (Consortium, 2013).
164 Principle components analysis was performed using approximately 10,000 common markers
165 in low LD ($r^2 < 0.004$), minor allele frequency (MAF) > 0.05 and 139 population outliers were
166 removed.
167
168 Given the differential association of potential risk factors at each subsite (i.e. smoking,
169 alcohol and HPV infection)(Thomas et al., 2018), we performed stratified MR analyses for
170 oral and oropharyngeal cancer to evaluate potential heterogeneity in effects. For this, we
171 used GWAS summary data on a subset of 2,990 oral and 2,641 oropharyngeal cases and the
172 6,585 common controls in the GAME-ON GWAS (Lesseur et al., 2016).
173
174 **Statistical analysis**
175
176 Two-sample MR was conducted using the "TwoSampleMR" package in R (version 3.5.3), by
177 integrating SNP associations for each metabolic trait (exposure, sample 1) with those for
178 oral and oropharyngeal cancer in GAME-ON (outcome, sample 2). We only used genetic

179 variants reaching GWAS significance ($p < 5\times10^{-8}$). The nearest gene was identified using
180 SNPsnap and a distance of +/- 500 kb (Pers, Timshel, & Hirschhorn, 2014). Firstly, metabolic
181 trait-associated SNPs were extracted from oral and oropharyngeal cancer summary
182 statistics. Exposure and outcome summary statistics were harmonised using the
183 "*harmonise_data*" function of the TwoSampleMR package so that variant effect estimates
184 corresponded to the same allele. Palindromic SNPs were identified and corrected using
185 allele frequencies where possible (alleles were aligned when minor allele frequencies were <
186 0.3, or were otherwise excluded). For each SNP in each exposure, individual MR effect-
187 estimates were calculated using the Wald method (SNP-outcome beta/SNP-exposure beta)
188 (Wald, 1940). Multiple SNPs were then combined into multi-allelic instruments using
189 random-effects inverse-variance weighted (IVW) meta-analysis.
190
191 IVW estimates may be vulnerable to bias if genetic instruments are invalid and are only
192 unbiased in the absence of horizontal pleiotropy or when horizontal pleiotropy is balanced
193 (Hemani, Bowden, & Smith, 2018). We therefore performed additional sensitivity analyses
194 to evaluate the potential for unbalanced horizontal pleiotropy using weighted median
195 (Bowden, Smith, Haycock, & Burgess, 2016), weighted mode (Hartwig, Smith, & Bowden,
196 2017) and MR-Egger (Bowden, Davey Smith, & Burgess, 2015) methods which are described
197 in detail elsewhere (Lawlor DA, 2019). In short, the weighted median stipulates that at least
198 50% of the weight in the analysis stems from valid instruments. Weighted mode returns an
199 unbiased estimate of the causal effect if the cluster with the largest weighted number of
200 SNPs for the weighted model are all valid instruments. Instruments are weighted by the
201 inverse variance of the SNP-outcome association.(Hartwig et al., 2017)
202

203 Finally, MR-Egger provides reliable effect estimates even if variants are invalid and the
204 Instrument Strength Independent of Direct Effect (InSIDE) assumption is violated (Bowden
205 et al., 2015). The InSIDE assumption states that the association between genetic instrument
206 and exposure should not be correlated with an independent path from instrument to the
207 outcome. In the presence of unbalanced pleiotropy when the InSIDE assumption is violated,
208 then the MR-Egger result may be biased (Lawlor DA, 2019). Gene variants must be valid
209 instruments and where there was evidence of violation of the negligible measurement error
210 (NOME) assumption (Bowden, Del Greco, et al., 2016), this was assessed using the I^2 statistic
211 and MR-Egger was performed with simulation extrapolation (SIMEX) correction for bias
212 adjustment (Bowden, Del Greco, et al., 2016). The variance of each trait explained by the
213 genetic instrument (R^2) was estimated and used to perform power calculations (Brion,
214 Shakhbazov, & Visscher, 2013). F-statistics were also generated. An F-statistic lower than 10
215 was interpreted as indicative of a weak instrument bias (Lawlor, Harbord, Sterne, Timpson,
216 & Davey Smith, 2008). To further assess the robustness of MR estimates, we examined
217 evidence of heterogeneity across individual SNPs using the Cochran Q-statistic, which
218 indicates the presence of invalid instruments (e.g., due to horizontal pleiotropy), if Q is
219 much larger than its degrees of freedom (No. of instrumental variables minus 1) (Bowden et
220 al., 2018). MR-PRESSO (Mendelian Randomization Pleiotropy RESidual Sum and Outlier) was
221 used to detect and correct for potential outliers (where Q-statistic $p < 0.05$) (Verbanck,
222 Chen, Neale, & Do, 2018).
223
224 **Instrument-risk factor effects**
225

226 Where there was evidence for an effect of a metabolic trait on oral or oropharyngeal cancer
227 risk in the primary MR analysis, we conducted further evaluation of the metabolic
228 instruments onto established HNC risk factors using two-sample MR. The largest available
229 GWAS were used for smoking initiation (a binary phenotype indicating whether an
230 individual had ever smoked in their life versus never smokers) (n=1,232,091) and alcoholic
231 drinks per week (defined as the average number of drinks per week aggregated across all
232 types of alcohol, n=941,280) from the GWAS and Sequencing Consortium of Alcohol and
233 Nicotine use (GSCAN) study (Liu et al., 2019). Summary statistics were also obtained from a
234 GWAS of general risk tolerance (n=939,908), derived from a meta-analysis of UK Biobank
235 (n=431,126) binary question *"Would you describe yourself as someone who takes risks?"*
236 and the 23andMe (n=508,782) question *"Overall, do you feel comfortable or uncomfortable*
237 *taking risks?"*. The GWAS of risk tolerance was based on one's tendency or willingness to
238 take risks, making them more likely to engage in risk-taking behaviours more generally
239 (Karlsson Linner et al., 2019). A strong genetic correlation between sexual behaviours and
240 risk tolerance has been shown previously (Gormley et al., 2022). Finally, given the known
241 association between HNC and lower socioeconomic position, we used MR to examine
242 educational attainment (defined by years of schooling) (J. J. Lee et al., 2018). Outcome beta
243 estimates reflect the standard deviation of the phenotype.
244

245 **Results**

246

247 F-statistics of genetic instruments for metabolic traits ranged from 33.3 – 133.6, indicating
248 sufficient instrument strength for MR analyses (**Supplementary Table 1**). Genetic
249 instruments were estimated to explain between 0.5% (FI) and 4% (BMI) of their respective

250 metabolic trait (**Supplementary Table 1**). Based on the results of prior observational studies
251 we would expect to detect OR of >1.10 for a clinically meaningful effect of metabolic traits
252 on oral and oropharyngeal cancer. **Supplementary Fig. 1A-C** displays power estimates for
253 MR analyses. In analyses where BMI was the exposure, we had 70% power to detect an
254 association with an OR of 1.2 or more at an α of 0.05 for combined oral and oropharyngeal
255 cancer. Power was lower for other metabolic traits and reduced when stratifying analyses
256 by subsite (**Supplementary Fig. 1**).
257
258 *Estimated effect of adiposity on oral and oropharyngeal cancer risk*
259 There was limited evidence of an effect of higher BMI or WHR on combined oral and
260 oropharyngeal cancer (OR IVW 0.89, 95%CI 0.72–1.09, p = 0.26, per 1 SD in BMI (4.81 kg/m^2)
261 and OR IVW 0.98, 95%CI 0.74–1.29, p = 0.88, per 1 SD in WHR (0.10 unit)) (**Table 1; Fig. 2;**
262 **Supplementary Fig. 2 & 3**). Results were consistent when analyses were stratified by subsite
263 (**Table 1**). WC, another measure of adiposity did show a protective direction of effect (OR
264 IVW 0.73, 95%CI 0.52–1.02, p = 0.07, per 1 SD increase in WC (0.09 unit)), particularly in the
265 oropharyngeal subsite (OR IVW 0.66, 95%CI 0.43–1.01, p = 0.06, per 1 SD increase in WC
266 (0.09 unit)) (**Table 1; Fig. 2; Supplementary Fig. 4**).
267
268 *Estimated effect of glycaemic traits on oral and oropharyngeal cancer risk*
269 There was limited evidence for an effect of genetically-proxied T2D on combined oral and
270 oropharyngeal cancer (OR IVW 0.92, 95%CI 0.84–1.01, p = 0.09, per 1-log unit higher odds of
271 T2D (**Table 1; Fig. 2; Supplementary Fig. 5**). Traits related to diabetes, including HbA_{1c}
272 resulted in a weak protective effect on combined oral and oropharyngeal cancer risk (OR
273 IVW 0.56, 95%CI 0.32–1.00, p = 0.05, per 1-log-unit % higher HbA_{1c}), which remained only in

274 the oral subsite (OR IVW 0.48, 95%CI 0.24–0.93, p = 0.03, per 1-log-unit % higher HbA_{1c})
275 following stratification (**Table 1; Fig. 2; Supplementary Fig. 6**). Conversely, there was limited
276 evidence of an effect for FG (OR IVW 1.06, 95%CI 0.68–1.66, p = 0.79, per 1-log unit increase
277 in mmol/L fasting glucose) (**Table 1; Fig. 2; Supplementary Fig. 7**) or FI (OR IVW 0.81, 95%CI
278 0.23–2.89, p = 0.75, per 1-log unit increase in mmol/L fasting insulin) on combined oral and
279 oropharyngeal cancer risk (**Table 1; Fig. 2; Supplementary Fig. 8**)
280
281 *Estimated effect of increased blood pressure oral and oropharyngeal cancer risk*
282 Finally, there was limited evidence for an effect of SBP on risk of combined oral and
283 oropharyngeal cancer (OR IVW 1.00, 95%CI 0.97–1.03, p = 0.89, per 1 unit mmHg increase in
284 systolic blood pressure) (**Table 1; Fig. 2; Supplementary Fig. 9**), which did not change when
285 stratified by subsite. However, there was some weak evidence for a protective effect of DBP
286 on risk of combined oral and oropharyngeal cancer (OR IVW 0.93, 95%CI 0.87–1.00, p = 0.05,
287 per 1 unit mmHg increase in diastolic blood pressure) (**Table 1; Fig. 2; Supplementary Fig.
288 10**).

289 **Table 1.** Mendelian randomization results of genetically-proxied metabolic traits with risk of oral and oropharyngeal cancer in GAME-ON

					IVW		Weighted median		Weighted mode		MR-Egger	
Exposure	**Outcome**	**Exposure/ Outcome source**	**Outcome N**	**Number of SNPs**	**OR (95%CI)**	**P**	**OR (95%CI)**	**P**	**OR (95%CI)**	**P**	**OR (95%CI)**	**P**
BMI	Oral and oropharyngeal cancer combined	Pulit *et al.* GWAS (Pulit et al., 2019)/ GAME-ON (Lesseur et al., 2016)	6,034	272	0.89 (0.72, 1.09)	0.26	0.71 (0.50, 1.00)	0.05	0.63 (0.37, 1.04)	0.07	0.66 (0.40, 1.10)	0.11
	Oral cancer		2,990	272	0.92 (0.71, 1.19)	0.53	0.83 (0.55, 1.28)	0.40	0.79 (0.38, 1.62)	0.52	0.75 (0.39, 1.41)	0.37
	Oropharyngeal cancer		2,641	272	0.89 (0.68, 1.15)	0.36	0.75 (0.50, 1.13)	0.17	0.53 (0.27, 1.03)	0.06	0.56 (0.29, 1.07)	0.08
WC	Oral and oropharyngeal cancer combined	Pulit *et al.* GWAS (Pulit et al., 2019)/ GAME-ON (Lesseur et al., 2016)	6,034	43	0.73 (0.52, 1.02)	0.07	0.64 (0.40, 1.05)	0.08	0.67 (0.36, 1.26)	0.22	0.43 (0.17, 1.08)	0.08
	Oral cancer		2,990	43	0.82 (0.53, 1.26)	0.36	0.66 (0.36, 1.21)	0.18	0.67 (0.32, 1.39)	0.29	0.54 (0.17, 1.76)	0.31
	Oropharyngeal cancer		2,641	43	0.66 (0.43, 1.01)	0.06	0.56 (0.30, 1.05)	0.07	0.37 (0.17, 0.83)	0.02	0.30 (0.09, 0.98)	0.05
WHR	Oral and oropharyngeal cancer combined	Shungin *et al.* GWAS (Shungin et al., 2015)/ GAME-ON (Lesseur et al., 2016)	6,034	176	0.98 (0.74, 1.29)	0.88	0.98 (0.64, 1.49)	0.92	0.95 (0.45, 2.00)	0.89	1.80 (0.87, 3.71)	0.11
	Oral cancer		2,990	176	1.18 (0.84, 1.65)	0.35	1.00 (0.58, 1.73)	0.99	0.69 (0.29, 1.67)	0.41	2.49 (1.02, 6.12)	0.05
	Oropharyngeal cancer		2,641	176	0.83 (0.59, 1.14)	0.25	0.88 (0.51, 1.50)	0.63	0.93 (0.37, 2.30)	0.87	1.19 (0.50, 2.86)	0.70
T2D	Oral and oropharyngeal cancer combined	Vujkovic *et al.* GWAS (Vujkovic et al., 2020)/ GAME-ON (Lesseur et al., 2016)	6,034	254	0.92 (0.84, 1.01)	0.09	0.85 (0.74, 0.97)	0.02	0.84 (0.71, 1.01)	0.06	0.91 (0.77, 1.09)	0.31
	Oral cancer		2,990	254	0.94 (0.84, 1.05)	0.27	0.84 (0.72, 0.99)	0.04	0.82 (0.66, 1.02)	0.08	0.88 (0.71, 1.08)	0.22
	Oropharyngeal cancer		2,641	254	0.94 (0.84, 1.05)	0.27	0.89 (0.73, 1.10)	0.29	1.02 (0.80, 1.30)	0.88	1.00 (0.81, 1.24)	0.99
HbA_{1c}	Oral and oropharyngeal cancer combined	Wheeler *et al.* GWAS (Wheeler et al., 2017)/ GAME-ON	6,034	37	0.56 (0.32, 1.00)	0.05	0.52 (0.23, 1.20)	0.12	0.54 (0.24, 1.21)	0.14	0.37 (0.13, 1.05)	0.07
	Oral cancer		2,990	37	0.48 (0.24, 0.93)	0.03	0.51 (0.18, 1.41)	0.19	0.44 (0.15, 1.29)	0.14	0.30 (0.09, 1.03)	0.06

	Oropharyngeal cancer	(Lesseur et al., 2016)	2,641	37	0.66 (0.31, 1.40)	0.28	0.49 (0.15, 1.57)	0.23	0.57 (0.18, 1.85)	0.35	0.43 (0.11, 1.68)	0.23
FG	Oral and oropharyngeal cancer combined	Lagou *et al.* GWAS (Lagou et al., 2021)/ GAME-ON (Lesseur et al., 2016)	6,034	28	1.06 (0.68, 1.66)	0.79	1.20 (0.62, 2.30)	0.59	1.13 (0.60, 2.12)	0.71	1.11 (0.48, 2.56)	0.80
	Oral cancer		2,990	28	1.05 (0.58, 1.92)	0.87	1.15 (0.48, 2.72)	0.75	0.99 (0.44, 2.23)	0.99	1.25 (0.39, 4.01)	0.70
	Oropharyngeal cancer		2,641	28	1.39 (0.77, 2.51)	0.28	1.24 (0.51, 3.03)	0.63	1.36 (0.59, 3.18)	0.48	1.38 (0.45, 4.18)	0.58
FI	Oral and oropharyngeal cancer combined	Lagou *et al.* GWAS (Lagou et al., 2021)/ GAME-ON (Lesseur et al., 2016)	6,034	17	0.81 (0.23, 2.89)	0.75	0.75 (0.20, 2.87)	0.68	0.60 (0.03, 10.79)	0.74	0.11 (0.001, 22.47)	0.43
	Oral cancer		2,990	17	0.96 (0.22, 4.16)	0.96	0.46 (0.08, 2.47)	0.37	0.45 (0.01, 19.02)	0.68	0.21 (0.0004, 107.21	0.63
	Oropharyngeal cancer		2,641	17	0.68 (0.16, 2.87)	0.59	0.66 (0.12, 3.67)	0.63	0.48 (0.05, 4.99)	0.55	0.09 (0.0002, 40.04)	0.45
SBP	Oral and oropharyngeal cancer combined	Evangelou *et al.* GWAS (Evangelou et al., 2018)/ GAME-ON (Lesseur et al., 2016)	6,034	83	1.00 (0.97, 1.03)	0.89	0.99 (0.94, 1.03)	0.55	0.98 (0.88, 1.09)	0.66	1.06 (0.92, 1.23)	0.39
	Oral cancer		2,990	83	1.01 (0.96, 1.06)	0.74	0.99 (0.93, 1.04)	0.65	0.95 (0.84, 1.08)	0.48	1.09 (0.90, 1.33)	0.37
	Oropharyngeal cancer		2,641	83	0.99 (0.95, 1.03)	0.65	0.99 (0.94, 1.05)	0.77	1.00 (0.88, 1.13)	0.94	1.03 (0.87, 1.23)	0.71
DBP	Oral and oropharyngeal cancer combined	Evangelou *et al.* GWAS (Evangelou et al., 2018)/ GAME-ON (Lesseur et al., 2016)	6,034	64	0.93 (0.87, 1.00)	0.05	0.94 (0.86, 1.04)	0.22	1.10 (0.88, 1.38)	0.42	0.99 (0.80, 1.24)	0.95
	Oral cancer		2,990	64	0.95 (0.87, 1.04)	0.26	0.96 (0.86, 1.07)	0.45	1.17 (0.88, 1.56)	0.28	0.97 (0.74, 1.27)	0.81
	Oropharyngeal cancer		2,641	64	0.92 (0.84, 1.00)	0.05	0.94 (0.84, 1.05)	0.29	1.10 (0.86, 1.41)	0.45	1.00 (0.75, 1.30)	0.93

Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals; P, *p*-value; BMI, body mass index; WC, waist circumference; WHR, waist-hip ratio; T2D, type 2 diabetes mellitus; FG, fasting glucose; FI, fasting insulin; HbA_{1c}, glycated haemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure. OR are expressed per 1 standard deviation (SD) increase in genetically predicted BMI (4.81 kg/m^2), WC (0.09 unit), WHR (0.10 unit), T2D (1-log unit higher odds of T2D), FG (1-log unit increase in mmol/L fasting glucose), FI (1-log unit increase in mmol/L fasting insulin), HbA_{1c} (1-log-unit % higher glycated haemoglobin), SBP (1 unit mmHg increase) and DBP (1 unit mmHg increase).

295 **Figure 2.** Mendelian randomization results of genetically-proxied metabolic disorders with

296 risk of oral and oropharyngeal cancer including sensitivity analyses in GAME-ON

297



298

299

300 Abbreviations: IVW, inverse variance weighted; OR, odds ratio with 95% confidence intervals; BMI, body mass index; WC, waist

301 circumference; WHR, waist-hip ratio; T2D, type 2 diabetes mellitus; FG, fasting glucose; FI, fasting insulin; HbA1c, glycated haemoglobin;

302 SBP, systolic blood pressure; DBP, diastolic blood pressure. OR are expressed per 1 standard deviation (SD) increase in genetically

303 predicted BMI (4.81 kg/m2), WC (0.09 unit), WHR (0.10 unit), T2D (1-log unit higher odds of T2D), FG (1-log unit increase in mmol/L

304 fasting glucose), FI (1-log unit increase in mmol/L fasting insulin), HbA1c (1-log-unit % higher glycated haemoglobin), SBP (1 unit mmHg

305 increase) and DBP (1 unit mmHg increase).

306

307 **Sensitivity analyses**

308

309 We conducted MR Egger, weighted median, and weighted mode analyses in addition to IVW

310 (**Table 1; Fig. 2**). The results of these analyses generally followed the same pattern as the

311 IVW results reported above, however, there were a number of exceptions. The results for
312 HbA1c were not robust to sensitivity testing ($p > 0.05$ across methods) (**Table 1; Fig. 2**). In
313 the analysis of T2D on combined oral and oropharyngeal cancer, the weighted median result
314 provided evidence for a weak protective effect (OR weighted median 0.85, 95%CI 0.74–0.97,
315 $p = 0.02$). This effect appeared mainly in the oral subsite (OR weighted median 0.84, 95%CI
316 0.72–0.99, $p = 0.04$). Furthermore, in the analysis of WC on oropharyngeal cancer risk, the
317 weighted mode supported IVW result, providing evidence of a protective effect (OR
318 weighted mode 0.37, 95%CI 0.17–0.83, $p = 0.02$) (**Table 1; Fig. 2**).
319
320 There was clear evidence of heterogeneity in the SNP effect estimates for IVW and MR
321 Egger regression for WHR (Q IVW 213.04, $p = 0.03$; Q MR Egger 209.24, $p = 0.04$), T2D (Q
322 IVW 328.24, $p < 0.01$; Q MR Egger 328.21, $p < 0.01$), FI (Q IVW 32.87, $p < 0.01$; Q MR Egger
323 31.63, $p < 0.01$) and DBP (Q IVW 95.82 $p < 0.01$; Q MR Egger 95.22, $p < 0.01$)
324 (**Supplementary Table 2**). MR-Egger intercepts were not strongly indicative of directional
325 pleiotropy (**Supplementary Table 3**), but there were outliers present on visual inspection of
326 scatter plots (**Supplementary Figs. 11-19**). MR-PRESSO identified 19 outliers for BMI, 2
327 outliers for WC, 12 outliers for WHR, 23 outliers for T2D, 4 outliers for HbA_{1c}, 1 outlier for
328 FG, 3 outliers for FI, 5 outliers for SBP, 7 outliers for DBP (**Supplementary Tables 4-5**). When
329 correcting for these outliers, this yielded effects consistent with the primary IVW analysis
330 except for adiposity and T2D instruments, which demonstrated a protective effect on
331 combined oral and oropharyngeal cancer risk when outliers were excluded: BMI (OR IVW
332 0.77, 95%CI 0.62–0.94, $p = 0.01$, per 1 SD in BMI (4.81 kg/m^2)); WC (OR IVW 0.65, 95%CI
333 0.47–0.89, $p = 0.01$, per 1 SD in WC (0.09 unit)), and T2D (OR IVW 0.91, 0.84–0.99, $p = 0.03$,
334 per 1-log unit higher odds of T2D) (**Supplementary Table 6**). Where there was evidence of

335 violation of the NOME assumption for WC, FI, SBP and DBP (i.e., I^2 statistic <0.90)
336 (**Supplementary Table 7**), MR-Egger was performed with SIMEX correction. SIMEX effects
337 were consistent with the null, except for SBP where an increased risk effect on combined
338 oral and oropharyngeal cancer was found (OR IVW 1.15, 95%CI 1.05–1.26, $p < 0.01$, per 1
339 unit mmHg increase in diastolic blood pressure) (**Supplementary Table 8**).
340
341 *Evaluating instrument-risk factor effects*
342 Where there was some evidence for an effect of BMI, WC, WHR , T2D , HbA_{1c} and DBP on
343 oral and oropharyngeal cancer, we carried out further MR analysis to determine causal
344 effects of these metabolic instruments on established risk HNC risk factors. Obesity-related
345 measures showed a strong causal effect on the risk of smoking initiation: BMI (Beta IVW
346 0.21 (standard error (SE) 0.03), $p < 0.001$, per 1 SD increase in BMI (4.81 kg/m2)), WC (Beta
347 IVW 0.21 (SE 0.05), $p < 0.001$, per 1 SD increase in WC (0.09 unit)) and WHR (Beta IVW 0.18
348 (SE 0.03), $p < 0.001$, per 1 SD increase in WHR (0.10 unit)) (**Supplementary Table 9**). There
349 was weaker evidence for an effect of BMI, WC, and genetic liability to T2D on consumption
350 of alcoholic drinks per week: BMI (Beta IVW -0.04 (SE 0.01), $p < 0.01$, per 1 SD increase in
351 BMI (4.81 kg/m2)), WC (Beta IVW -0.09 (SE 0.02), p < 0.001, per 1 SD increase in WC (0.09
352 unit)) and T2D (Beta IVW -0.02 (SE 0.01), $p < 0.001$, per 1-log unit higher odds of T2D). BMI
353 (Beta IVW 0.04 (SE 0.01), $p <0.001$, per 1 SD increase in BMI (4.81 kg/m2)) and WHR (Beta
354 IVW 0.04 (SE 0.02), $p = 0.02$, per 1 SD increase in WHR (0.10 unit)) were also estimated to
355 increase general risk tolerance. Similarly, increased BMI or WHR and genetic liability to T2D
356 were estimated to increase educational attainment (years of schooling): BMI (Beta IVW -
357 0.16 (SE 0.02), $p < 0.001$, per 1 SD increase in BMI (4.81 kg/m2)), WHR (Beta IVW -0.11 (SE
358 0.02), $p < 0.001$, per 1 SD increase in WHR (0.10 unit)), and T2D (Beta IVW -0.02 (SE 0.01), p

359 < 0.01, per 1-log unit higher odds of T2D). However, there was strong evidence of both
360 heterogeneity (**Supplementary Table 10**) and genetic pleiotropy (**Supplementary Table 11**)
361 across most instrument-risk factor effects. With the exception of alcohol drinks per week,
362 the estimated instrument-risk factor effects remained unchanged following the removal of
363 outlier SNPs detected by MR-PRESSO (**Supplementary Table 12**).
364

365 ## Discussion

366

367 In this MR study we found limited evidence to support a causal role of genetically-predicted
368 metabolic traits in oral and oropharyngeal cancer, suggesting the risk may have been
369 previously overestimated in observational studies. Where weak evidence for an effect was
370 found (i.e., a protective effect of HbA_{1c}), these results were not robust to sensitivity analysis,
371 including outlier correction. There was also strong evidence for instrument-risk factor
372 effects, suggesting smoking may be a mediator between obesity and HNC.
373

374 There are several biological mechanisms linking metabolic traits and cancer, but these have
375 not been well explored in HNC (Gatenby & Gillies, 2004; Grimberg, 2003; Tseng, Lin, Lin, &
376 Weng, 2014). Dysregulated metabolism is likely linked to the probability a cancer develops
377 and progresses, given that tumours must adapt to satisfy the bioenergetic and biosynthetic
378 demands of chronic cell proliferation via metabolic reprogramming, enhancing or
379 suppressing the activity of metabolic pathways relative to that in benign tissue (DeNicola &
380 Cantley, 2015). In the largest pooled analysis of 17 case-control studies, BMI was associated
381 with a higher risk of overall HNC, but when stratified by subsite the effect was mainly in the

382 larynx (HR 1.42, 95%CI 1.19–1.70 per 5 kg/m^2, $p < 0.001$) (Gaudet et al., 2015). Laryngeal
383 cancer was not included in our study given that GWAS summary data were not available for
384 this subsite and future analysis of this region is therefore warranted. BMI effects on both
385 the oral (HR 1.10, 95%CI 0.97–1.25, $p = 0.14$) and oropharyngeal cancer (HR 0.98, 95%CI
386 0.84–1.14, $p = 0.77$) subsites were consistent with the effects found in our study (oral
387 cancer OR 0.92, 95%CI 0.71–1.19, $p = 0.53$; oropharyngeal cancer OR 0.89, 0.68–1.15, $p =$
388 0.36) (Gaudet et al., 2015). Conversely, the same pooled analysis found an increased risk for
389 both WC (HR 1.09, 95%CI 1.03–1.16, $p = 0.006$) and WHR (HR 1.17, 95%CI 1.02–1.34, $p =$
390 0.02), mainly in the oral subsite which were not replicated in our MR analysis. Varying
391 patterns of results for these anthropometric measures have been found when stratifying by
392 smoking status within observational studies (Gaudet et al., 2015). The relationship between
393 obesity and HNC is complex. There appears to be a positive association between low BMI
394 (<18.5 kg/m^2) and HNC risk, and a protective effect of BMI on HNC risk in current smokers
395 but conversely, a higher risk in never smokers (Gaudet et al., 2015). This suggests smoking
396 is a confounder, both as an established risk factor for HNC and in its correlation with weight,
397 with nicotine affecting metabolic energy expenditure, leading to reduced calorie absorption
398 and appetite suppression (Williamson et al., 1991). Instrument-risk factor effect estimates
399 from this study suggest smoking is also a mediator, through which metabolic traits such as
400 BMI influence HNC risk.
401
402 Despite metabolic syndrome (including hypertension, central obesity, elevated triglyceride,
403 low HDL-C and insulin resistance) being strongly associated with common cancers such as
404 colorectal and breast (Esposito, Chiodini, Colao, Lenzi, & Giugliano, 2012), this does not
405 appear to be the case in head and neck cancer. A recent prospective study of 474,929

406 participants from UK Biobank investigating the effect of metabolic syndrome suggested
407 those with the condition had no increased HNC risk (HR 1.05, 95%CI 0.90–1.22, $p = 0.560$)
408 (Jiang et al., 2021). No definitive causal effects were detected for individual components of
409 metabolic syndrome components either, supporting our MR results. While another large
410 meta-analysis found individuals with T2D have an elevated risk of oral cancer (Gong et al.,
411 2015), other more recent studies have found this effect to be mostly in laryngeal subsite (HR
412 1.25, 95%CI 1.12–1.40) which again we could not investigate in this study (H.-B. Kim et al.,
413 2021). Hypertension is the most consistently reported metabolic trait to have an
414 observational association with HNC risk across the subsites (Christakoudi et al., 2020; H.-B.
415 Kim et al., 2021; S.-Y. Kim et al., 2019; Seo et al., 2020; Stocks et al., 2012). We did not
416 identify a clear effect of either SBP or DBP on oral or oropharyngeal cancer using MR, again
417 suggesting the possibility of residual confounding in observational studies.
418
419 MR was employed in this study in an attempt to overcome the drawbacks of conventional
420 epidemiological studies. However, there are a number of limitations with using this
421 approach and if MR assumptions are violated, this too can generate spurious conclusions.
422 While there was no evidence of weak instrument bias (F statistics > 10), there was
423 heterogeneity present in at least four of the instruments (WHR, T2D, FI and DBP). This is
424 expected to some extent, given that we are instrumenting multiple biological pathways that
425 contribute to complex metabolic phenotypes. The use of multiple related instruments for
426 each metabolic trait may, however, provide some additional confidence in the overall
427 findings. Given the low percentage of variation explained (R^2) for some instruments, as well
428 as the relatively small number of oral and oropharyngeal cancer cases, power to detect an
429 effect may have been an issue in some of our analyses.

430

431 As with observational studies, there may be issues of measurement error or
432 misclassification in genetic epidemiology, given BMI is simply a function of mass and height
433 and does not specifically measure adiposity. However, BMI has been shown to be an
434 acceptable proxy when used in large samples sizes, correlating with both total body fat
435 (Browning et al., 2011) and total abdominal adipose tissue (Ross, Léger, Morris, de Guise, &
436 Guardo, 1992), which is thought to present a greater health risk than fat deposited
437 elsewhere. Furthermore, we used a range of adiposity measures including WC and WHR,
438 which may be better proxies of abdominal adiposity, compared to BMI (C. M. Lee, Huxley,
439 Wildman, & Woodward, 2008). SNPs used to proxy these metabolic traits, particularly
440 obesity-related measures BMI, WC and WHR were strongly associated with smoking. Given
441 the heterogeneity of these complex metabolic traits, future work could further examine
442 their pathway specific effects (Udler et al., 2018).

443

444 **Conclusion**

445

446 Overall, there was limited evidence for an effect of genetically-proxied metabolic traits on
447 oral and oropharyngeal cancer risk. These findings suggest metabolic traits may not be
448 effective modifiable risk factors to prioritise as part of future prevention strategies in head
449 and neck cancer. The effect of metabolic traits on the risk of this disease may have been
450 overestimated in previous observational studies, but these cannot be directly compared
451 given the differences in methodological approaches and the interpretation of estimates.
452 Smoking appears to act as a mediator in the relationship between obesity and HNC.

453 Although there is no clear evidence that changing body mass will reduce of increase the risk
454 of HNC directly, dental and medical teams should be aware of the risk of smoking in those
455 who are overweight and therefore the greater risk of cancer when providing smoking
456 cessation and appropriate weight loss advice.
457
458
459 **References**
460

461 Bowden, J., Davey Smith, G., & Burgess, S. (2015): Mendelian randomization with invalid
462 instruments: effect estimation and bias detection through Egger regression.
463 *International Journal of Epidemiology,* ***44***, 512-525.

464 Bowden, J., Del Greco, M. F., Minelli, C., Smith, G. D., Sheehan, N. A., & Thompson, J. R.
465 (2016): Assessing the suitability of summary data for two-sample Mendelian
466 randomization analyses using MR-Egger regression: the role of the I-2 statistic.
467 *International Journal of Epidemiology,* ***45***, 1961-1974.

468 Bowden, J., Smith, G. D., Haycock, P. C., & Burgess, S. (2016): Consistent Estimation in
469 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
470 Estimator. *Genetic Epidemiology,* ***40***, 304-314.

471 Bowden, J., Spiller, W., Del Greco, F., Sheehan, N., Thompson, J., Minelli, C., & Smith, G. D.
472 (2018): Improving the visualization, interpretation and analysis of two-sample
473 summary data Mendelian randomization via the Radial plot and Radial regression.
474 *International Journal of Epidemiology,* ***47***, 1264-1278.

475 Brion, M. J., Shakhbazov, K., & Visscher, P. M. (2013): Calculating statistical power in
476 Mendelian randomization studies. *International Journal of Epidemiology, **42***, 1497-
477 1501.

478 Browning, L. M., Mugridge, O., Dixon, A. K., Aitken, S. W., Prentice, A. M., & Jebb, S. A.
479 (2011): Measuring abdominal adipose tissue: comparison of simpler methods with
480 MRI. *Obesity facts, **4***, 9-15.

481 Cao, Z., Li, S., Xu, F., Yang, X., Wang, Y., Zheng, X., & Yang, H. (2020): Association of obesity
482 status and metabolic syndrome with site-specific cancers: a population-based cohort
483 study. *British Journal of Cancer, **123***, 1336-1344.

484 Carreras-Torres, R., Johansson, M., Haycock, P. C., Relton, C. L., Davey Smith, G., Brennan,
485 P., & Martin, R. M. (2018): Role of obesity in smoking behaviour: Mendelian
486 randomisation study in UK Biobank. *BMJ (Clinical research ed.), **361***, k1767-k1767.

487 Carter, A. R., Borges, M.-C., Benn, M., Tybjærg-Hansen, A., Davey Smith, G., Nordestgaard,
488 B. G., & Lawlor, D. A. (2019): Combined Association of Body Mass Index and Alcohol
489 Consumption With Biomarkers for Liver Injury and Incidence of Liver Disease: A
490 Mendelian Randomization Study. *JAMA Network Open, **2***, e190305-e190305.

491 Carter, A. R., Gill, D., Davies, N. M., Taylor, A. E., Tillmann, T., Vaucher, J., . . . Dehghan, A.
492 (2019): Understanding the consequences of education inequality on cardiovascular
493 disease: mendelian randomisation study. *BMJ, **365***, l1855.

494 Centers for Disease Control and Prevention. (2021). Obesity and Cancer [Internet] [cited
495 2022 Jun 18]. Retrieved from

https://www.cdc.gov/cancer/obesity/index.htm#:~:text=Being%20overweight%20or%20having%20obesity,the%20United%20States%20each%20year.

Christakoudi, S., Kakourou, A., Markozannes, G., Tzoulaki, I., Weiderpass, E., Brennan, P., . . . Tsilidis, K. K. (2020): Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition. *International Journal of Cancer, **146***, 2680-2693.

Consortium, O. (2013): Consortium launches genotyping effort. *Cancer Discov, **3***, 1321-1322.

Conway, D. I., Purkayastha, M., Chestnutt, I. G. (2018): The changing epidemiology of oral cancer: definitions, trends, and risk factors. *British Dental Journal, **225***, 867-873.

Davey, R. C. (2004): The obesity epidemic: too much food for thought? *British Journal of Sports Medicine, **38***, 360-363.

Davey Smith, G., & Hemani, G. (2014): Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Human Molecular Genetics, **23***, R89-98.

DeNicola, G. M., & Cantley, L. C. (2015): Cancer's Fuel Choice: New Flavors for a Picky Eater. *Mol Cell, **60***, 514-523.

Diaz, Y., Duarte-Salles, T., Recalde, M., Freisling, H., Davila-Batista, V., Leitzmann, M., & Romieu, I. (2021): Body mass index and waist circumference in relation to the risk of 26 types of cancer: a prospective cohort study of 3.5 million adults in Spain. *BMC Medicine, **19***, 10-10.

Dudding, T., Johansson, M., Thomas, S. J., Brennan, P., Martin, R. M., & Timpson, N. J. (2018): Assessing the causal association between 25-hydroxyvitamin D and the risk

517 of oral and oropharyngeal cancer using Mendelian randomization. *International*
518 *Journal of Cancer, **143***, 1029-1036.

519 Esposito, K., Chiodini, P., Colao, A., Lenzi, A., & Giugliano, D. (2012): Metabolic syndrome
520 and risk of cancer: a systematic review and meta-analysis. *Diabetes Care, **35***, 2402-
521 2411.

522 Evangelou, E., Warren, H. R., Mosen-Ansorena, D., Mifsud, B., Pazoki, R., Gao, H., . . . the
523 Million Veteran, P. (2018): Genetic analysis of over 1 million people identifies 535
524 new loci associated with blood pressure traits. *Nature Genetics, **50***, 1412-1425.

525 Gatenby, R. A., & Gillies, R. J. (2004): Why do cancers have high aerobic glycolysis? *Nature*
526 *Reviews Cancer, **4***, 891-899.

527 Gaudet, M. M., Kitahara, C. M., Newton, C. C., Bernstein, L., Reynolds, P., Weiderpass, E., . . .
528 Gapstur, S. M. (2015): Anthropometry and head and neck cancer:a pooled analysis of
529 cohort data. *International Journal of Epidemiology, **44***, 673-681.

530 Gillison, M. L., Chaturvedi, A. K., Anderson, W. F., & Fakhry, C. (2015): Epidemiology of
531 Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. *J Clin*
532 *Oncol, **33***, 3235-3242.

533 Gong, Y., Wei, B., Yu, L., & Pan, W. (2015): Type 2 diabetes mellitus and risk of oral cancer
534 and precancerous lesions: a meta-analysis of observational studies. *Oral Oncology,*
535 ***51***, 332-340.

536 Gormley, M., Dudding, T., Kachuri, L., Burrows, K., Chong, A. H. W., Martin, R. M., . . .
537 Richmond, R. C. (2022): Investigating the effect of sexual behaviour on

538 oropharyngeal cancer risk: a methodological assessment of Mendelian
539 randomization. *BMC Medicine,* ***20***, 40.

540 Gormley, M., Yarmolinsky, J., Dudding, T., Burrows, K., Martin, R. M., Thomas, S., . . .
541 Richmond, R. C. (2021): Using genetic variants to evaluate the causal effect of
542 cholesterol lowering on head and neck cancer risk: A Mendelian randomization
543 study. *PLOS Genetics,* ***17***, e1009525.

544 Gribsholt, S. B., Cronin-Fenton, D., Veres, K., Thomsen, R. W., Ording, A. G., Richelsen, B., &
545 Sorensen, H. T. (2020): Hospital-diagnosed overweight and obesity related to cancer
546 risk: a 40-year Danish cohort study. *Journal of Internal Medicine,* ***287***, 435-447.

547 Grimberg, A. (2003): Mechanisms by which IGF-I may promote cancer. *Cancer biology &*
548 *therapy,* ***2***, 630-635.

549 Hartwig, F. P., Smith, G. D., & Bowden, J. (2017): Robust inference in summary data
550 Mendelian randomization via the zero modal pleiotropy assumption. *International*
551 *Journal of Epidemiology,* ***46***, 1985-1998.

552 Hashibe, M., Brennan, P., Chuang, S. C., Boccia, S., Castellsague, X., Chen, C., . . . Boffetta, P.
553 (2009): Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck
554 Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology
555 Consortium. *Cancer Epidemiology Biomarkers & Prevention,* ***18***, 541-550.

556 Hemani, G., Bowden, J., & Smith, G. D. (2018): Evaluating the potential role of pleiotropy in
557 Mendelian randomization studies. *Human Molecular Genetics,* ***27***, R195-R208.

558 Jiang, H., Zhou, L., Jiang, K., Huang, X., He, Q., & Yuan, J. (2021): The effect of metabolic
559 syndrome on head and neck cancer incidence risk: a population-based prospective
560 cohort study. *Cancer & metabolism,* ***9***, 25-25.

561 Johnson, D. E., Burtness, B., Leemans, C. R., Lui, V. W. Y., Bauman, J. E., & Grandis, J. R.
562 (2020): Head and neck squamous cell carcinoma. *Nature Reviews Disease Primers,* ***6***,
563 92.

564 Karlsson Linner, R., Biroli, P., Kong, E., Meddens, S. F. W., Wedow, R., Fontana, M. A., . . .
565 Beauchamp, J. P. (2019): Genome-wide association analyses of risk tolerance and
566 risky behaviors in over 1 million individuals identify hundreds of loci and shared
567 genetic influences. *Nature Genetics,* ***51***, 245-257.

568 Kim, H.-B., Kim, G.-J., Han, K.-d., & Joo, Y.-H. (2021): Changes in metabolic syndrome status
569 and risk of laryngeal cancer: A nationwide cohort study. *PLoS One,* ***16***, e0252872-
570 e0252872.

571 Kim, S.-Y., Han, K.-d., & Joo, Y.-H. (2019): Metabolic Syndrome and Incidence of Laryngeal
572 Cancer: A Nationwide Cohort Study. *Scientific Reports,* ***9***, 667.

573 Lagou, V., Mägi, R., Hottenga, J.-J., Grallert, H., Perry, J. R. B., Bouatia-Naji, N., . . . Insulin-
574 related traits, C. (2021): Sex-dimorphic genetic effects and novel loci for fasting
575 glucose and insulin variability. *Nature Communications,* ***12***, 24.

576 Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N., & Davey Smith, G. (2008):
577 Mendelian randomization: using genes as instruments for making causal inferences
578 in epidemiology. *Statistics in Medicine,* ***27***, 1133-1163.

579 Lawlor DA, W. K., Borges MC, Palmer T, Hartwig FP, Hemani G, Bowden JA. . (2019): A
580 Mendelian Randomization dictionary: Useful definitions and descriptions for
581 undertaking, understanding and interpreting Mendelian Randomization studies.

582 Lee, C. M., Huxley, R. R., Wildman, R. P., & Woodward, M. (2008): Indices of abdominal
583 obesity are better discriminators of cardiovascular risk factors than BMI: a meta-
584 analysis. *J Clin Epidemiol,* ***61***, 646-653.

585 Lee, J. J., Wedow, R., Okbay, A., Kong, E., Maghzian, O., Zacher, M., . . . Social Science
586 Genetic Association, C. (2018): Gene discovery and polygenic prediction from a
587 genome-wide association study of educational attainment in 1.1 million individuals.
588 *Nature Genetics,* ***50***, 1112-1121.

589 Lesseur, C., Diergaarde, B., Olshan, A. F., Wunsch, V., Ness, A. R., Liu, G., . . . Brennan, P.
590 (2016): Genome-wide association analyses identify new susceptibility loci for oral
591 cavity and pharyngeal cancer. *Nature Genetics,* ***48***, 1544-1550.

592 Liu, M. Z., Jiang, Y., Wedow, R., Li, Y., Brazel, D. M., Chen, F., . . . Psychiat, H. A. I. (2019):
593 Association studies of up to 1.2 million individuals yield new insights into the genetic
594 etiology of tobacco and alcohol use. *Nature Genetics,* ***51***, 237.

595 Pers, T. H., Timshel, P., & Hirschhorn, J. N. (2014): SNPsnap: a Web-based tool for
596 identification and annotation of matched SNPs. *Bioinformatics,* ***31***, 418-420.

597 Pulit, S. L., Stoneman, C., Morris, A. P., Wood, A. R., Glastonbury, C. A., Tyrrell, J., . . .
598 Lindgren, C. M. (2019): Meta-analysis of genome-wide association studies for body

599 fat distribution in 694 649 individuals of European ancestry. *Human Molecular*
600 *Genetics,* ***28***, 166-174.

601 Ross, R., Léger, L., Morris, D., de Guise, J., & Guardo, R. (1992): Quantification of adipose
602 tissue by MRI: relationship with anthropometric variables. *J Appl Physiol (1985),* ***72***,
603 787-795.

604 Saarela, K., Tuomilehto, J., Sund, R., Keskimaki, I., Hartikainen, S., & Pukkala, E. (2019):
605 Cancer incidence among Finnish people with type 2 diabetes during 1989-2014.
606 *European Journal of Epidemiology,* ***34***, 259-265.

607 Sanderson, E., Glymour, M. M., Holmes, M. V., Kang, H., Morrison, J., Munafò, M. R., . . .
608 Davey Smith, G. (2022): Mendelian randomization. *Nature Reviews Methods Primers,*
609 ***2***, 6.

610 Seo, J.-H., Kim, Y.-D., Park, C.-S., Han, K.-d., & Joo, Y.-H. (2020): Hypertension is associated
611 with oral, laryngeal, and esophageal cancer: a nationwide population-based study.
612 *Scientific Reports,* ***10***, 10291.

613 Shungin, D., Winkler, T. W., Croteau-Chonka, D. C., Ferreira, T., Locke, A. E., Mägi, R., . . .
614 Mohlke, K. L. (2015): New genetic loci link adipose and insulin biology to body fat
615 distribution. *Nature,* ***518***, 187-196.

616 Smith, G. D., & Ebrahim, S. (2003): 'Mendelian randomization': can genetic epidemiology
617 contribute to understanding environmental determinants of disease? *International*
618 *Journal of Epidemiology,* ***32***, 1-22.

619 Stocks, T., Van Hemelrijck, M., Manjer, J., Bjorge, T., Ulmer, H., Hallmans, G., . . . Stattin, P.
620 (2012): Blood pressure and risk of cancer incidence and mortality in the Metabolic
621 Syndrome and Cancer Project. *Hypertension (Dallas, Tex. : 1979),* ***59***, 802-810.

622 Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F.
623 (2021): Global cancer statistics 2020: GLOBOCAN estimates of incidence and
624 mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for*
625 *Clinicians*.

626 Thomas, S. J., Penfold, C. M., Waylen, A., & Ness, A. R. (2018): The changing aetiology of
627 head and neck squamous cell cancer: A tale of three cancers? *Clinical*
628 *Otolaryngology,* ***43***, 999-1003.

629 Tseng, K. S., Lin, C., Lin, Y. S., & Weng, S. F. (2014): Risk of head and neck cancer in patients
630 with diabetes mellitus: a retrospective cohort study in Taiwan. *JAMA Otolaryngol*
631 *Head Neck Surg,* ***140***, 746-753.

632 Udler, M. S., Kim, J., von Grotthuss, M., Bonàs-Guarch, S., Cole, J. B., Chiou, J., . . . Florez, J.
633 C. (2018): Type 2 diabetes genetic loci informed by multi-trait associations point to
634 disease mechanisms and subtypes: A soft clustering analysis. *PLoS Med,* ***15***,
635 e1002654.

636 Verbanck, M., Chen, C. Y., Neale, B., & Do, R. (2018): Publisher Correction: Detection of
637 widespread horizontal pleiotropy in causal relationships inferred from Mendelian
638 randomization between complex traits and diseases. *Nature Genetics,* ***50***, 1196.

639 Vujkovic, M., Keaton, J. M., Lynch, J. A., Miller, D. R., Zhou, J., Tcheandjieu, C., . . . Program,
640 V. A. M. V. (2020): Discovery of 318 new risk loci for type 2 diabetes and related
641 vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis.
642 *Nature Genetics,* ***52***, 680-691.

643 Wald, A. (1940): The Fitting of Straight Lines if Both Variables are Subject to Error. *The*
644 *Annals of Mathematical Statistics,* ***11***, 284-300, 217.

645 Ward, H. A., Wark, P. A., Muller, D. C., Steffen, A., Johansson, M., Norat, T., . . . Riboli, E.
646 (2017): Measured Adiposity in Relation to Head and Neck Cancer Risk in the
647 European Prospective Investigation into Cancer and Nutrition. *Cancer epidemiology,*
648 *biomarkers & prevention : a publication of the American Association for Cancer*
649 *Research, cosponsored by the American Society of Preventive Oncology,* ***26***, 895-904.

650 Wheeler, E., Leong, A., Liu, C. T., Hivert, M. F., Strawbridge, R. J., Podmore, C., . . . Meigs, J.
651 B. (2017): Impact of common genetic determinants of Hemoglobin A1c on type 2
652 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-
653 wide meta-analysis. *PLoS Med,* ***14***, e1002383.

654 Williamson, D. F., Madans, J., Anda, R. F., Kleinman, J. C., Giovino, G. A., & Byers, T. (1991):
655 Smoking Cessation and Severity of Weight Gain in a National Cohort. *New England*
656 *Journal of Medicine,* ***324***, 739-745.

657 World Health Organization (WHO). (2022). WHO European Regional Obesity Report 2022.
658 [Internet] [cited 2022 Jun 06].

659

660 **Ethics approval and consent to participate**

661 All studies included as part of the GAME-ON network obtained approval and consent from
662 their respective institutions.
663
664 **Consent for publication**
665 Not applicable.
666
667 **Availability of data and materials**
668 Summary-level analysis was conducted using publicly available GWAS data as cited. Full
669 summary statistics for the GAME-ON outcome data GWAS can be accessed via dbGAP
670 (OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1, August
671 2017 at: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-
672 bin/study.cgi?study_id=phs001202.v1.p1). There is one selected publication by Lesseur et
673 al. related to this data (Lesseur et al., 2016). Exposure data is publicly available from the
674 relevant studies and via the IEU Open GWAS (https://gwas.mrcieu.ac.uk/). MR analyses
675 were conducted using the "TwoSampleMR" package in R (version 3.5.3). A copy of the code
676 and all files used in this analysis is available at GitHub
677 (https://github.com/MGormley12/metabolic_trait_hnc_mr.git).
678
679 **Competing interests**
680 The authors declare that they have no competing interests
681
682 **Funding**
683 M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and is
684 currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship.

685 This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z].
686 For the purpose of open access, the author has applied a CC BY public copyright licence to
687 any Author Accepted Manuscript version arising from this submission. R.C.R. is a de Pass VC
688 research fellow at the University of Bristol. J.T. is supported by an Academy of Medical
689 Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust,
690 Global Challenges Research Fund (GCRF), the Government Department of Business, Energy
691 and Industrial strategy, the British Heart Foundation and Diabetes UK (SBF004\1079). A.R.N.
692 was supported by the National Institute for Health Research (NIHR) Bristol Biomedical
693 Research Centre which is funded by the National Institute for Health Research (NIHR) and is
694 a partnership between University Hospitals Bristol NHS Foundation Trust and the University
695 of Bristol. Department of Health and Social Care disclaimer: The views expressed are those
696 of the authors and not necessarily those of the NHS, the NIHR or the Department of Health
697 and Social Care. This publication presents data from the Head and Neck 5000 which
698 contributes to international VOYAGER and HEADSpAcE head and neck cancer consortia. The
699 Head and Neck 5000 study was a component of independent research funded by the
700 National Institute for Health Research (NIHR) under its Programme Grants for Applied
701 Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of
702 the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
703 Core funding was also provided through awards from Above and Beyond, University
704 Hospitals Bristol and Weston Research Capability Funding and the NIHR Senior Investigator
705 award to A.R.N. Human papillomavirus (HPV) serology was supported by a Cancer Research
706 UK Programme Grant, the Integrative Cancer Epidemiology Programme (C18281/A20919).
707 The VOYAGER study was supported in part by the US National Institute of Dental and
708 Craniofacial Research (NIDCR; R01 DE025712). The genotyping of the HNC cases and

709 controls was performed at the Center for Inherited Disease Research (CIDR) and funded by
710 the US National Institute of Dental and Craniofacial Research (NIDCR; 1X01HG007780-0).
711 E.E.V, C.B. and D.L. are supported by Diabetes UK (17/0005587). E.E.V, and C.B. are
712 supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer
713 Research Fund International grant programme (IIG_2019_2009). M.G., T.D., G.D.S, E.E.V.,
714 R.C.R, and C.B. are part of the Medical Research Council Integrative Epidemiology Unit at
715 the University of Bristol supported by the Medical Research Council (MC_UU_00011/1,
716 MC_UU_00011/5, MC_UU_00011/6, MC_UU_00011/7).
717

718 **Authors' contributions**

719 M.G., E.E.V., R.C.R. and C.B. conceived the study and M.G. carried out data curation and
720 analysis. Head and neck cancer summary genetic data was obtained through multiple
721 collaborations from studies lead by A.R.N., S.J.T., and M.P. as well as members of VOYAGER
722 and HEADSpAcE consortia. The initial manuscript was drafted by M.G., E.E.V. and C.B..
723 Expert guidance on MR methodology was provided by T.D., C.B. and G.D.S. All authors M.G.,
724 T.D., S.J.T., J.T., A.R.N., M.P., D.L., G.D.S., R.C.R., E.E.V., and C.B. contributed to the
725 interpretation of the results and critical revision of the manuscript. All authors read and
726 approved the final manuscript. M.G. supervisory team includes R.C.R., E.E.V., J.T., A.R.N and
727 G.D.S.